Abstract
Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Current Vascular Pharmacology
Title:Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Volume: 13 Issue: 5
Author(s): Theodora Nakouti, Apostolos K.A. Karagiannis, Konstantinos Tziomalos and Evangelos Cholongitas
Affiliation:
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Export Options
About this article
Cite this article as:
Nakouti Theodora, Karagiannis K.A. Apostolos, Tziomalos Konstantinos and Cholongitas Evangelos, Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease, Current Vascular Pharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570161112666141121112612
DOI https://dx.doi.org/10.2174/1570161112666141121112612 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Structure - Function Analysis of Peptide Analogs of SQSPA with Respect to α-glucosidase and α-amylase Inhibition
Protein & Peptide Letters Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Ticagrelor: A Novel Drug for an Old Problem
Recent Patents on Cardiovascular Drug Discovery Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Hypertension in Polycystic Ovary Syndrome: Novel Insights
Current Hypertension Reviews Role of Inflammation in Diabetic Nephropathy
Current Diabetes Reviews The Potential Roles of Gamma-Glutamyltransferase Activity in the Progression of Atherosclerosis and Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Comparison of Thermal Foot Maps between Diabetic Patients with Neuropathic, Vascular, Neurovascular, and No Complications
Current Diabetes Reviews Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Resveratrol as a Protective Molecule for Neuroinflammation: A Review of Mechanisms
Current Pharmaceutical Biotechnology